Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
Outline of Final Research Achievements |
Patients with metastatic and disseminated gastrointestinal cancers show poor prognosis and the development of anti-metastasis therapy to prevent cancer metastasis and dissemination is an important issue. Here, we developed a drug screening system using colorectal cancer (CRC) cells with fluorescence probe for epithelial-mesenchymal transition (EMT). Anti-inflammatory drug aspirin inhibited inflammatory cytokine-induced EMT and prevented peritoneal dissemination of CRC cells. In the future, we need to evaluate the therapeutic effect of aspirin in the metastasis and dissemination of non-CRC cells.
|